+ Reply to Thread
Page 50 of 210 FirstFirst ... 40 48 49 50 51 52 60 100 150 ... LastLast
Results 491 to 500 of 2095

Thread: Replicel

  1. #491
    Junior Member
    Join Date
    Oct 2010
    Posts
    18

    Default Losing hope

    Personally i'm seriously doubting any of these companies will come with a solution by 2015. I remember 2 years ago i read that Aderans would complete Phase II by end of last year - 2011. Lo and behold, we are into 2012 and now they say they're planning on completing Phase II in 2013!!! I once read that Dr. Rassman from baldingblog.com got many negative comments on his site after stating that hair cloning is very far away, and wouldn't be ready for another 10 years (Dr. Bernstein says the same thing). I see now what he meant. There is no way in hell i'll ever see a semi-full head of hair in my life, at least not in the youthful years that it will matter. Hair transplant probably isn't a good solution either, as one small strip from the donor area in the back will never be enough to cover an eventual Norwood 7 in my case. I'll just shave my head and live life. By the time these useless bastards release a solution, i'll be too old to care for it. God forsaken useless bastards!

  2. #492
    Senior Member
    Join Date
    Aug 2011
    Posts
    2,004

    Default

    Wouldn't kill you to exude some positivity and optimism mate.

  3. #493
    Junior Member
    Join Date
    Oct 2010
    Posts
    18

    Default

    Sorry clandestine, just very frustrating to lose all my hair while in my 20s and knowing there isn't any real solution for at least half a decade.

  4. #494
    Senior Member
    Join Date
    Aug 2011
    Posts
    2,004

    Default

    No need to be sorry, I feel for you. This is a tough battle, and I can only imagine how hard it's been for those members who are a little older now, not having had any new treatment options to hope for or look forward to.

    All we can do is stay optimistic. And never should we let this affliction dictate how we live our lives.

    That said, this condition is indeed life-changing. Hair, in most cases, is a big part of who we are as a person. It is intrinsically part of our identity for the better part of our youth. Here's to hoping for better treatment options in the near future.

    Cheers.

  5. #495
    Senior Member
    Join Date
    Nov 2011
    Posts
    830

    Default Replicel update interview

    NBT Two-Minute Drill with David Hall, CEO of Replicel Life Sciences

    January 30, 2012

    We recently interviewed David Hall, CEO of Replicel Life Sciences Inc. (OTCBB:REPCF), on their upcoming Phase I/IIa clinical trial results “reveal” 90 or so days away.

    With positive results expected from their current Phase I/IIa trial, Replicel will move immediately into a 100-patient dosing trial. Replicel hopes to build an overwhelming set of successful data for the patented RepliCel™ procedure for minimally invasive hair cell growth and implantation.

    With two successful data-sets in hand, Replicel intends to sell its entire hair growth and implantation business to the highest Big Pharma/Big Bio bidder. NBT analyses the value of the follicular regeneration industry at about $500 million—or more than $10 a share with an expected 10 million share dilution from money raising activities in 2012.

    NBT: In your pre-clinical trials with specially modified mice you saw 50% hair growth with cosmetically attractive density 100% of the time…Replicel is now roughly 90 days away from the release of your Phase I/IIa human trial results from 19 human patients. What should investors be looking at most?

    DHall: These are the key data points: First and foremost, interim analysis is human safety. To date, we have seen no safety issues and frankly, we do not expect any. The second key interim object is an indication of efficacy at 6 months or specifically, the increase in density of existing hair and indication of new hair follicles. We will use all that data in the filing of our Investigational Medical Product Dossier which will go to the regulators for our Phase II/b 100-pateint dosing trial.

    Remember this is the first look at 6 months for all the clinical trial patients…all patients will be measured again for hair growth and density at 12 and 24 months as well. We establish a baseline of results from day zero and then you measure results at 6, 12 and 24 months against that original baseline.

    NBT: How do you measure results at the initial look?

    DHall: The contract research organization (“CRO”) takes microscopic images of every patient…each patient dossier is reviewed at 6 months and all data is cleaned for 100% properly entered data. If any data is missing, the CRO and the clinic coordinate to enter the missing data.

    Each patient has had one side of their scalp injected with a placebo and one side injected with their own dermal sheath cup cells. Our patents, as you know, are around the growth and implantation of the highly specialized dermal sheath cup cells vs. less-specialized cells. The CRO does 100% of the data collection. All data is blinded so RepliCel cannot review the data until it is un-blinded.

    NBT: How much hair growth do you expect at 6 months?

    DHall: Well first you have to answer that question in the context of existing “gold standard” surgical hair transplantation. In state-of-the-art micro-surgical procedures, in the first few months all the hair fibre in the area of the surgery falls out and begins to reappear around the six month time frame. It normally can take up to 18 months for the success or failure of the micro-surgery to become evident. In that context, virtually any amount of hair growth or hair density at 6 months for the RepliCel™ procedure would give us the data we need to immediately pursue the Phase II/b 100-patient dose-ranging clinical trial. What we are looking for is demonstration of increased fiber density of the existing hair from base line, as well as indication of new follicular growth.

    We have also taken biopsies from a random sampling of patients to look, at a microscopic level, to see growth below the scalp. We are looking at these biopsies multi-dimensionally. That is to say, we are not just looking at the topical site—we are looking at small biopsies of the injection sites…looking at the angles of hair growth. It’s not good enough to grow hair, you have to have the appropriate growth orientations. That means cosmetically acceptable results…the animal trial got appropriate angles growing in a natural angle…not clustered in one little patchy area.

    What we are ultimately looking for is evidence of cosmetically acceptable hair regeneration and increased density of hair follicles initially in the transplanted region of the scalp. Eventually, we expect to see actual regeneration of existing hair follicles NEAR the implanted region…as we saw in the pre-clinical animal trials. Regeneration of dormant hair follicles is the “secret sauce” of our procedure.

    Even in the worst case scenario—i.e. zero response above the initial baseline at 6 months, we continue to gather the data through 12 and 24 months. Responders can come later, as is seen with micro transplants.

    In short…this is pretty straight forward science: if you have ANY growth from the implanted autologous dermal sheath cup cells, one should expect to have MORE growth of both those new follicles and from dormant hair follicles that have regenerated.

    NBT: What else is Replicel working on in the hair regeneration arena?

    DHall: In parallel to our clinical trials, we are validating a number of cell markers for dermal sheath cup cells. These markers are very important because with their unique expression we could accelerate both our dermal sheath cup cell isolation and replication protocols. Speeding-up/improving both these aspects of the RepliCel™ procedure are helpful for its commercial application.

    Each of these dermal sheath cells express certain proteins, proteins you ONLY find in the dermal sheath cup cells. To date, we have identified quite a number of unique protein markers. With these unique identifiers or “markers” we can almost completely automate our process and thus greatly accelerate the RepliCel™ procedure for the patient/clinician.

    In short, as we create more efficiency and speed in the isolation and replication of the dermal sheath cup cells significant value is created for the company—more procedures per day/week/month means more revenues for the clinician.

    NBT: When do you get an endpoint for this “hunt”?

    DHall: There is no magic number for protein markers…we already have many targets. But by year end, we will get to the final end points. Remember, automating our isolation and growth procedures really adds significant value to the eventual sale of the RepliCel™ procedure. Automating the cell isolation also helps in the regulatory process…both in speed and in validating that the dermal sheath cells we are isolating and growing are ALWAYS the same cells and not a mix with other unwanted cell. We have a manual process right now for the isolation and regeneration protocol. For the next clinical trial they will use the manual procedure and we will seek to integrate the automated process in a new set of trials.

    NBT: Anything else on your regulatory approval risk?

    DHall: The beauty of working with autologous cells…meaning the patient’s own cells…is that we are using a particular cell population whose only purpose in life is to instruct a cellular cascade to grow hair fibers. Ours is a 100% completely different regulatory environment than if we were taking one type of cell and try to manipulate it into another type of cell…that kind of cell-based therapy is a VERY difficult regulatory environment…because every step of the way the cells have to be proven to be the SAME induced cell.

    It’s really simple: in using a patient’s own cells we are only increasing the concentration of the cells…NOT changing those cells…all of which has MUCH lower safety and regulatory hurdles.

    NBT: You have made it clear that assuming you have the clinical data to prove your procedure is the new standard in hair regeneration you will seek to sell the division in its entirety to a multi-national Big Pharma player. Why?

    DHall: The biotech space is growing again…Big Pharm/Big Bio have BIG PROBLEMS with their patent cliffs and there is only so much M&A they can do at the high end. So, they have begun to change their strategies by partnering and acquiring technology further upstream.

    If we show hair growth and continued growth in our 50 men/50 women dosing trials conducted under a clinical trial harmonized both for European and US FDA regulations, it will be an attractive asset. There is a very Darwinian nature in the Big Pharma/Big Bio ecosystem. Big Pharma and Big Bio are on the top of the “food chain”…and it is NO secret they need BIG numbers from new long-lived patented products to move the needle for their valuation. That is why we are doing everything to FDA standards. No shortcuts. If our science wins the day, the valuation of the RepliCel™ procedure given the $5 billion worldwide annual market for hair restoration products and services will be obviously enormous.

    If we work hard and smart every day, we get a little closer to that reality.

  6. #496
    Senior Member
    Join Date
    Aug 2011
    Posts
    2,004

    Default

    Great share, Maradona. Thanks for the read.

    Quote Originally Posted by Maradona View Post
    NBT: You have made it clear that assuming you have the clinical data to prove your procedure is the new standard in hair regeneration you will seek to sell the division in its entirety to a multi-national Big Pharma player. Why?

    DHall: The biotech space is growing again…Big Pharm/Big Bio have BIG PROBLEMS with their patent cliffs and there is only so much M&A they can do at the high end. So, they have begun to change their strategies by partnering and acquiring technology further upstream.
    This part made me uneasy for some reason, however.

  7. #497
    Senior Member
    Join Date
    Nov 2011
    Posts
    830

    Default

    Quote Originally Posted by southasian View Post
    Personally i'm seriously doubting any of these companies will come with a solution by 2015. I remember 2 years ago i read that Aderans would complete Phase II by end of last year - 2011. Lo and behold, we are into 2012 and now they say they're planning on completing Phase II in 2013!!! I once read that Dr. Rassman from baldingblog.com got many negative comments on his site after stating that hair cloning is very far away, and wouldn't be ready for another 10 years (Dr. Bernstein says the same thing). I see now what he meant. There is no way in hell i'll ever see a semi-full head of hair in my life, at least not in the youthful years that it will matter. Hair transplant probably isn't a good solution either, as one small strip from the donor area in the back will never be enough to cover an eventual Norwood 7 in my case. I'll just shave my head and live life. By the time these useless bastards release a solution, i'll be too old to care for it. God forsaken useless bastards!
    be optimistic mate, imo. Replicel is the only solution for you and for me, the only problem is money and time. If replicel doesn't work, nothing else will, but that's my opinion after LONG LONG reading and studying.

    Let's just hope there's no stopping to replicel.


    On a Side note: replicel's stock is MOVING ON UP! ...to the east side...

  8. #498
    Senior Member
    Join Date
    May 2011
    Posts
    1,046

    Default

    Quote Originally Posted by clandestine View Post
    Great share, Maradona. Thanks for the read.



    This part made me uneasy for some reason, however.
    This should actually reassure you. There is no reason whatsoever that Big Pharma would bury such a treatment if they could have it themselves to make billions. This is the next Lipitor in terms of profits if it does what it says on the tin. Think $20 billion a year not 5. A lot of people are scared of HTs and think they're a scam so imagine the real interest if this works.

  9. #499
    Senior Member
    Join Date
    Aug 2011
    Posts
    2,004

    Default

    Quote Originally Posted by Follicle Death Row View Post
    This should actually reassure you. There is no reason whatsoever that Big Pharma would bury such a treatment if they could have it themselves to make billions. This is the next Lipitor in terms of profits if it does what it says on the tin. Think $20 billion a year not 5. A lot of people are scared of HTs and think they're a scam so imagine the real interest if this works.
    True, perhaps my skepticism is unfounded. Something about the wording 'Big Pharma' is just slightly off putting for some reason. Thanks for the perspective.

  10. #500
    Senior Member
    Join Date
    Feb 2011
    Posts
    876

    Default

    South Asian, I agree with you that it is so damn frustrating when these companies keep pushing back their timelines. Sometimes I wish that these companies were founded by men suffering from hair loss because only some one who directly suffers from hair loss really knows how devastating hair loss can be for a person. Those who don't suffer from it can't understand it, I know this first hand. If the founders of some of these companies really understood the devastation of hair loss, then they perhaps would be more determined to get something out to us as quickly as possible, knowing that it is unbearable for us to live even a few more years longer with this baldness shit. I really wish that these companies would at least put out some interim treatment to tide us over until a true cure is found. With regards to Rassman, he's totally full of shit. He always says that hair multiplication and new treatments/cures are so far away. He only says this shit for his own benefit. He's afraid that if he says something like "hair multiplication" is right around the corner", then people will forego his hair transplants and wait for more effective treatments or a cure. He wants more people to get hair transplants (preferably with him) so downgrades all of these new potential treatments so people will rush off and get a hair transplant with him. He honestly makes me sick.
    That being said, I really do believe that we have to remain positive. I believe that Replicel has better methodology than Aderans, because their methodology has been researched for longer, their projections are higher, and their scientists are some of the best in the world. I don't believe that Aderans even had those high hopes. I really like what Histogen was doing as well. And there might even be people in the Far East using stem cells to regrow hair that we're unaware of. For example, I remember a Japanese scientist named Mariko Yamaki who was attempting to use mesenchymal stem cells to regrow hair. I really wish that we had many more people/companies working on a hair loss cure.

Tags for this Thread

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts

» IAHRS

hair transplant surgeons

» The Bald Truth

» Recent Threads

1800 graft repair case results by Dr. Lindsey
Yesterday 08:38 AM
Last Post By Dr. Lindsey
Yesterday 08:38 AM
Navigating the German Job Market as a Kenyan Citizen
11-04-2023 06:31 AM
Last Post By Keegan212
Yesterday 03:51 AM
DR HAKAN DOGANAY/ 4500 GRAFTS / Implanter Pen+FUE
03-26-2024 04:15 PM
Last Post By Hakan Doganay, MD
03-26-2024 04:15 PM
The Mane Event for Thursday, June 15th, 2023
06-15-2023 02:59 PM
Last Post By gisecit34
03-26-2024 08:05 AM